Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2009 Fall-Winter;41(3-4):174-8.

The efficacy and safety of two fixed combinations: timolol-dorzolamide-brimonidine versus timolol-dorzolamide. A prospective, randomized, double-masked, multi-center, 6-month clinical trial

Leopoldo Martín Baiza-Durán  1 , Jaime Alvarez-Delgado, Angélica Yussett Contreras-Rubio, Javier Medrano-Palafox, Anel De Luca-Brown, Homero Casab-Rueda, Marco Antonio Cortés-Gastélum, Miguel Jorge Garcidueñas-Mejía, Pedro Gómez-Bastar, Félix Gil-Carrasco, Curt Hartleben-Matkin, Jesús Jiménez-Román, Miguel Luis Moreno-Marín, José Antonio Paczka-Zapata, Gustavo Velasco-Gallegos, Mario Vergara-Sinta
Affiliations
  • PMID: 20214051
Randomized Controlled Trial

The efficacy and safety of two fixed combinations: timolol-dorzolamide-brimonidine versus timolol-dorzolamide. A prospective, randomized, double-masked, multi-center, 6-month clinical trial

Leopoldo Martín Baiza-Durán et al. Ann Ophthalmol (Skokie). 2009 Fall-Winter.

Abstract

We compared the efficacy and safety of a new fixed combination of timolol 0.5%/odorzolamide 20%/brimonidine 0.2% in ophthalmic solution versus a fixed combination of timolol 0.5%/dorzolamide 2% in patients with open-angle glaucoma or ocular hypertension. The fixed triple combination was significantly more efficient in mean intraocular pressure reduction from baseline throughout the six-month follow-up.

PubMed Disclaimer

Publication types

MeSH terms